FOLR1 and non-small cell lung carcinoma: However, about ∼20% of adenocarcinoma patients and the majority of squamous cell and non-small cell lung cancer patients will not benefit from the pafolacianine probe due to a lack of folate alpha receptors in the primary tumors.